COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT

摘要

The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEV A®). A preferred example of a KIT kinase inhibitor that can be used in practicing this invention is OSI-930 and OSI-817.